ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

ProQR Therapeutics N.V.NASDAQ: PRQR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of €12.02M fell 2.4% year over year, behind the +12.6% change in trailing-twelve-month research & development. Sequentially, it rose 22.3% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.

Context

  • Research & development amounted to 266.5% of revenue in FY2025, up 74.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +12.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€12.02M+22.3% QoQ
Last fiscal yearDec 2025
€40.72M+12.0% YoY
LTMMar 2026
€44.34M+12.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.4%——
1 year+12.0%——
3-year CAGR-7.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
40.72M EUR
Year-over-year change
+12.0%
4-year CAGR
-0.9%

Research & Development vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +12.6% is the 5th highest of 11, against a peer median of -0.8%.
  • Research & development amounts to 329.9% of revenue for PRQR, versus a peer median of 717.1%.
PRQR Competitors
Research & Development for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$143.25M USD+11.2%+28.8%2496.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M USD-32.1%-16.3%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$101.99M USD+14.6%+8.4%46.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M USD-44.3%-8.8%216.6%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$92.92M USD+60.8%+57.0%—
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M USD-62.3%-19.9%171.1%
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+25.1%1217.6%
ZURAZura Bio LimitedLTM Mar 2026$46.35M USD+48.2%+21.1%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€44.34M EUR+12.6%-7.1%329.9%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$19.19M USD-29.2%-8.6%—
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M USD-12.8%-16.7%3625.8%
Peer median (excluding PRQR) —-0.8%-0.1%717.1%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.